CD41 T cell recovery during suppression of HIV replication: an international comparison of the immunological efficacy of antiretroviral therapy in North America, Asia and Africa.
- Geng, Elvin H
- Neilands, Torsten B
- Thièbaut, Rodolphe
- Bwana, Mwebesa Bosco
- Nash, Denis
- Moore, Richard D
- Wood, Robin
- Zannou, Djimon Marcel
- Althoff, Keri N
- Lim, Poh Lian
- Nachega, Jean B
- Easterbrook, Philippa J
- Kambugu, Andrew
- Little, Francesca
- Nakigozi, Gertrude
- Nakanjako, Damalie
- Kiggundu, Valerian
- Ki Li, Patrick Chung
- Bangsberg, David R
- Fox, Matthew P
- Prozesky, HansW
- Hunt, Peter W
- Davies, Mary-Ann
- Reynolds, Steven J
- Egger, Matthias
- Yiannoutsos, Constantin T
- Vittinghoff, Eric V
- Deeks, Steven G
- Martin, Jeffrey N
DOIAbstract
BACKGROUND Even among HIV-infected patients who fully suppress plasma HIV RNA replication on antiretroviral therapy, genetic (e.g. CCL3L1 copy number), viral (e.g. tropism) and environmental (e.g. chronic exposure to microbial antigens) factors influence CD4 recovery. These factors differ markedly around the world and therefore the expected CD4 recovery during HIV RNA suppression may differ globally. METHODS We evaluated HIV-infected adults from North America, West Africa, East Africa, Southern Africa and Asia starting non-nucleoside reverse transcriptase inhibitorbased regimens containing efavirenz or nevirapine, who achieved at least one HIV RNA level <500/ml in the first year of therapy and observed CD4 changes during HIV RNA su...
Add to ORKG